Drug Database
QU

quinidine bisulfate (Kiditard)

✓ Approved

Adare Pharma Solutions · SCN5A · 小分子

什么是 quinidine bisulfate?

quinidine bisulfate 是一种小分子,由Adare Pharma Solutions研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Kiditard
公司Adare Pharma Solutions
药物类别小分子
分子靶点SCN5A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

quinidine bisulfate 作用于 1 个分子靶点:

SCN5Asodium voltage-gated channel alpha subunit 5 (CMD1E, SSS1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

quinidine bisulfate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersArrhythmia✓ Approved

相关研究文献

PubMedBBA advances2026-11-17

Inhibition of the OCTN1-mediated acetylcholine transport by quinidine and verapamil.

Pochini Lorena L, Cerbelli Maria Iolanda MI, Galluccio Michele M, Mariem Omar Ben OB et al.

The non-neuronal cholinergic system plays an important role in certain human diseases, such as cancer. The Novel Organic Cation Transporter, OCTN1, mediates the efflux of acetylcholine in the frame of this system, from both normal and tumour cells, providing a localised, non-neuronal source of acetylcholine that plays a crucial role in regulating fundamental cellular processes, including proliferation, differentiation, migration and immune responses. Therefore, inhibiting OCTN1-mediated acetylcholine release with repurposed drugs could represent a novel therapeutic approach. Data previously obtained by computational analysis identified quinidine and verapamil as strong OCTN1 binders. These drugs have been experimentally validated for their effects on acetylcholine transport using proteoliposome assays with both recombinant OCTN1 and OCTN1 extracted from the A549 cell line. This experimental system, based on a single-protein approach, is not affected by interferences, allowing us to describe a mixed-type of inhibition for both drugs, indicating that the binding sites for the substrate and the drugs do not fully overlap. Importantly, a trans-inhibition effect by the two drugs on the acetylcholine release was revealed. The experimental approach used proved advantageous in the highly reliable and rapid identification of the mechanism of inhibition by approved drugs.

PMID 43041283
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression.

Fagiolini Andrea A, Cuomo Alessandro A, Corrivetti Giulio G, Pinzi Mario M et al.

Dextromethorphan is extensively O-demethylated by cytochrome P450 2D6 (CYP2D6) to dextrorphan, and the two molecules do not share a target profile. Dextrorphan is the more potent N-methyl-D-aspartate (NMDA) channel blocker; the parent compound is the more potent serotonin transporter inhibitor; their sigma-1 affinities are comparable, so differences in sigma-1 engagement depend on exposure rather than intrinsic affinity. CYP2D6 activity therefore does not scale exposure to a fixed pharmacology; it determines which pharmacology is expressed. This review develops that principle and extends it to a three-agent system. From published unbound concentrations and functional potencies, we calculate a model-derived fractional-target-engagement index. Under the base-case inputs, CYP2D6 inhibition raises the serotonergic index approximately fourfold while reducing the NMDA channel index; deterministic sensitivity analysis shows that the direction is robust to one-at-a-time 0.5-fold to 2-fold perturbations but not to all joint extreme assumptions. Quinidine and bupropion are analyzed as mechanistically distinct proofs of concept, and quinidine-derived exposure estimates are not treated as quantitative surrogates for the dextromethorphan-bupropion steady state. The framework is then applied to the untested question of whether a boosted dextromethorphan combination and esketamine are redundant or complementary. The agents share an NMDA channel mechanism, while CYP2B6 pathway overlap remains a hypothesis-generating observation rather than evidence of clinically relevant competition. No controlled data on the three-agent combination exist, and no therapeutic recommendation is made.

PMID 43028281
阅读全文 →
PubMedReviews in cardiovascular medicine2026-11-05

Efficacy of Quinidine in Brugada Syndrome: A Literature Review.

Bazoukis George G, Andreakis Emmanouil E, Saplaouras Athanasios A, Liu Tong T et al.

Brugada syndrome (BrS) is an inherited arrhythmogenic disorder associated with an increased risk of ventricular fibrillation (VF) and sudden cardiac death. Quinidine and hydroquinidine are currently used to prevent ventricular arrhythmias in BrS. This review summarizes the available evidence on the efficacy, safety, and clinical applications of these drugs in BrS. Ten studies involving more than 300 patients with BrS were analyzed. Quinidine or hydroquinidine therapy prevented VF inducibility in 42.9-90% of cases and reduced recurrent arrhythmic events by approximately 60-70%. Among patients with implantable cardioverter-defibrillators (ICDs), reductions in both appropriate and inappropriate shock counts were observed. Gastrointestinal intolerance was the most common side effect, occurring in 20-30% of patients, with drug discontinuation in up to 26%. QT prolongation was infrequent, and serious proarrhythmic events were rare. Despite these benefits, quinidine remains unavailable or difficult to access in many regions, limiting its widespread clinical use. In conclusion, quinidine and hydroquinidine exert antiarrhythmic effects in BrS and reduce the recurrence of ventricular arrhythmias, particularly among ICD-treated or high-risk patients. Although therapy is constrained by gastrointestinal intolerance and limited availability, low-dose regimens may be better tolerated while maintaining efficacy. These agents can be considered, in selected patients, as adjuncts or alternatives to device therapy; meanwhile, further multicenter studies are warranted to confirm long-term safety, determine optimal dosing, and improve global accessibility.

PMID 42985528
阅读全文 →
PubMedPharmaceutical development and technology2026-10-31

pH/GSH-responsive dual chitosan/PLA-coated cobalt ferrite nanoparticles for targeted and selective quinidine delivery in hepatocellular carcinoma.

Anter Esraa E, Elshami Fawzya I FI, Shereef Hadeer A HA, Abdou Safaa N SN et al.

Drug repurposing using smart nanocarriers may help overcome chemoresistance and poor tumor selectivity in hepatocellular carcinoma (HCC). Here, a pH/GSH-responsive dual chitosan/polylactic acid coated cobalt ferrite nanoparticle system (QL-CS/PLA-CFO NPs) has been explored to deliver QL for treating HCC. QL-CS/PLA-CFO NPs were prepared via ionotropic gelation and w/o/w emulsion with high loading (64.8%) and excellent stability (+28.0 mV). Comparative formulations, chitosan-only QL-CS-CFO (50.9%, -10.5 mV) and nonmagnetic QL-CS/PLA (60.7%, -21.0 mV), elucidated the roles of coating architecture and magnetic core. QL-CS/PLA-CFO NPs released 10.8% at pH 7.4 versus ∼95% at pH 4.5 with 10 mM GSH over 180 h, following quasi-Fickian diffusion kinetics. Encapsulation increased the WI38/HepG2 IC₅₀ ratio from 1.12 to 1.93 through controlled endosomal release and protecting normal cells, with ∼1.2% hemolysis and enhanced DPPH antioxidants IC₅₀ (47.9 vs. 71.9 μg/mL for free QL). DNA-binding studies revealed PLA-CFO synergy, yielding 38-fold enhanced affinity versus free QL through a minor-groove binding mode. Molecular docking suggested a potential interaction between quinidine and the HCC-associated biomarker glypican-3 (PDB 3GJB), supporting future investigation of its biological relevance. QL-CS/PLA-CFO NPs represent a promising platform for selective QL delivery in HCC, warranting further in vivo evaluation.

PMID 42965930
阅读全文 →
PubMedHealthcare (Basel, Switzerland)2026-10-27

Off-Label Dextromethorphan/Bupropion for Emotional Lability Following Resection of an IDH-Mutant Astrocytoma: A Case Report.

Hill Olivia O, Imlay Riley R, Chalia Ankit A, Kalluri Sowjanya S et al.

Pseudobulbar affect (PBA) is characterized by recurrent, involuntary episodes of crying or laughing that may be disproportionate or incongruent with an individual's underlying mood. Although dextromethorphan/quinidine is FDA-approved for PBA, clinical experience with dextromethorphan/bupropion for this indication remains limited. We describe a 42-year-old woman with a history of resected right frontal IDH-mutant grade 2 astrocytoma who developed recurrent episodes of involuntary crying associated with emotional lability and subjective executive difficulties. At initial behavioral-health evaluation, the Center for Neurologic Study-Lability Scale (CNS-LS) score was 21/35 and the Patient Health Questionnaire-9 (PHQ-9) score was 9. The phenomenology of the crying episodes, clinical examination, neurological history, imaging surveillance, and consideration of alternative explanations supported a working clinical diagnosis of PBA, although the CNS-LS was used as a symptom measure rather than a stand-alone diagnostic test. Treatment with dextromethorphan/quinidine was associated with an initial reduction in crying episodes and CNS-LS score, followed by recurrence of symptoms. Because further treatment modification was limited by insurance coverage, an off-label trial of dextromethorphan/bupropion was subsequently initiated. Six weeks later, the CNS-LS score had decreased to 10 and the PHQ-9 score to 4. Subjective executive difficulties also improved. A temporary interruption in dextromethorphan/bupropion was followed by recurrence of crying episodes, with improvement after treatment was resumed. This case describes an association between off-label dextromethorphan/bupropion exposure and improvement in emotional-lability symptoms in a patient with a complex neurological and psychiatric presentation. The findings are hypothesis-generating and cannot establish efficacy or causality because of the single-patient design, absence of repeated CNS-LS assessments at all visits, and concomitant medication changes. Controlled studies are needed to determine whether dextromethorphan/bupropion has a therapeutic role in PBA.

PMID 42940575
阅读全文 →
PubMedJournal of dairy science2026-10-23

Controlling ammonia concentrations in calf hutches with sodium bisulfate.

Casper David P DP, Robbins Randall D RD

Neonatal calves are susceptible to respiratory irritation and lung damage via elevated ammonia concentrations in calf facilities. The study objective evaluated the addition of Sodium Bisulfate (SBS; SurpHace; Jones-Hamilton) to reduce ammonia concentrations in calf hutches. Ninety Holstein male calves were blocked by body weight (BW) and randomly assigned to 1 of 2 treatments starting on June 4, 2025. Treatments were 1): Control: no SBS applied to calf hutch wheat straw bedding and 2): 454 g of SBS applied twice per week on Tuesday and Saturday mornings after feeding. SBS was applied with a Scotts WIZZ grass seeder to achieve even distribution of SBS in the hutches. Fresh chopped straw was added again on July 7 and ground soyhulls were added on July 14 and July 21 with the experiment ending on July 30. Ammonia readings were collected weekly starting wk 3 on Thursday mornings following feeding using a single personal NH3 gas detector (Model FD-80A (Forensics Detectors, Rolling Hills Estates, CA). The use of SBS reduced (P < 0.01) ammonia concentrations by approximately 85% (10.5 and 1.63 mg/kg for Control and SBS, respectively). There was a treatment by week interaction with the greatest reductions occurring during wk 7 and 8. Calves with SBS added to their bedding had increased (P < 0.02) BW gain (30.3 and 33.9 kg) and average daily gains (ADG; 541 and 605 g/d) approximately 12%. There was a tendency for increased calf starter consumption (0.63 and 0.73 kg/d) and a tendency for a treatment by week interaction demonstrating increased calf starter intake during wk 6, 7, and 8 for calf hutches receiving SBS compared with Control hutches. Feed conversions (0.495 and 0.511 kg/kg) were similar among both hutch treatments. Heart girth gain (12.5 and 14.5 cm) was improved for calves housed in hutches receiving SBS compared with Control hutches while remaining frame measurements were similar among calves housed in hutches without or with SBS. Scour scores were similar among calves housed in both hutch treatments. SBS was effective in reducing calf hutch ammonia concentrations by 85%, which supported improved BW gains, ADG, calf starter intake, and heart girth gains.

PMID 42913828
阅读全文 →

注册免费账户还可查看另外 8009 篇文献

免费注册查看全部文献 →

了解更多quinidine bisulfate